This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Su, C-C. Articles by Chen, C-Y. Search for Related Content PubMed PubMed Citation Articles by Su, C-C. Articles by Chen, C-Y. Social Bookmarking                         What's this?

CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity

Department of Internal Medicine, National Taiwan University College of Medicine

W-Y. Shau

Graduate Institute of Epidemiology, National Taiwan University College of Public Health, Taipei, Taiwan, ROC

C-R. Wang

Department of Internal Medicine, National Taiwan University College of Medicine

C-Y. Chuang

Department of Internal Medicine, National Taiwan University College of Medicine

C-Y. Chen

Department of Internal Medicine, National Taiwan University College of Medicine

CD69 is an early T cell activation marker. In order to investigate whether the disease activity of systemic lupus erythematosus (SLE) is correlated with T cell hyperactivity as well as B cell hyperactivity, we measured the CD69 to CD3 ratio (CD69/CD3) of peripheral blood mononuclear cells (PBMCs) from 42 SLE patients and 18 healthy controls. To assess B cell activation, we measured the levels of anti-dsDNA, complement C3 and C4. Disease activity was assessed with the SLE disease activity index (SLEDAI) score. The mean value (± standard deviation) of CD69/CD3 for SLE patients (3.34 ± 0.486) and healthy controls (0.92 ± 0.015) were significantly different (P < 0.05). CD69/CD3, anti-dsDNA, C3 and C4 were all significantly correlated with SLEDAI (r = 0.50, 0.51, -0.68, -0.31, respectively, P < 0.05). CD69/CD3 could explain 25.4% of the variance in SLEDAI, and 6.7% of the variance that was independent of anti-dsDNA, C3 and C4. In patients with SLEDAI scores which were discordant with anti-dsDNA, C3 and C4 values, CD69/ CD3 still showed high correlation with SLEDAI. We conclude that CD69/CD3, which detects T cell activation, is correlated with SLEDAI scores. Thus, T cell activation contributes part of the disease activity independent of B cell activity. This marker can complement in the estimation of disease activity when levels of anti-dsDNA, C3 and C4 fail to show good correlation.

Key Words: CD69 • CD3 • systemic lupus erythematosus • SLEDAI

Lupus, Vol. 6, No. 5, 449-454 (1997)
DOI: 10.1177/096120339700600507


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Hong, C. Huang, S. Wang, and B. Lin The ethyl acetate extract of alfalfa sprout ameliorates disease severity of autoimmune-prone MRL-lpr/lpr mice Lupus, March 1, 2009; 18(3): 206 - 215. [Abstract] [PDF]

				A Suarez, P Lopez, J Gomez, and C Gutierrez Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids Ann Rheum Dis, November 1, 2006; 65(11): 1512 - 1517. [Abstract] [Full Text] [PDF]

				S Giannouli, M Voulgarelis, P D Ziakas, and A G Tzioufas Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment Ann Rheum Dis, February 1, 2006; 65(2): 144 - 148. [Abstract] [Full Text] [PDF]

				A Anand, G S Dean, K Quereshi, D A Isenberg, and P M Lydyard Characterization of CD3+CD4-CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers Lupus, August 1, 2002; 11(8): 493 - 500. [Abstract] [PDF]

				X. Yu, T. Matsui, M. Otsuka, T. Sekine, K. Yamamoto, K. Nishioka, and T. Kato Anti-CD69 Autoantibodies Cross-React with Low Density Lipoprotein Receptor-Related Protein 2 in Systemic Autoimmune Diseases J. Immunol., January 15, 2001; 166(2): 1360 - 1369. [Abstract] [Full Text] [PDF]